The medication will be sold under the brand name Journavx for $15.50 per pill, according to Vertex Pharmaceuticals, the company that developed the new drug. The FDA's sign-off on the medication ...

The new campaign stars former NFL quarterback Alex Smith, whose leg injury during a 2018 game led to a case of ...

On Thursday, the Food and Drug Administration (FDA) granted approval to Vertex Pharmaceuticals' non-opioid painkiller pill, a new alternative for pain relief that does not carry the risk of addiction.

New non-opioid pain killer get FDA approval for acute pain. Patients are taking note. Also demonstrated efficacy, just not ...

On January 30th, in a landmark decision that could reshape the way acute pain is treated in the United States, the FDA approved suzetrigine (brand name, Journavx), a first-in-class non-opioid ...

Journavx's approval is an "important public health milestone," according to Jacqueline Corrigan-Curay, acting director of the FDA's Center for Drug Evaluation and Research (CDER). "A new non ...

Vertex also won FDA approval in January for Journavx, a non-opioid targeting acute pain. I'm especially optimistic about the commercial prospects for Journavx. It's the first new class of pain ...

The biopharmaceutical industry is positioned for continued recovery, driven by recent FDA approvals and billion-dollar ...

Investors eye Vertex’s Q1 for Alyftrek and Journavx momentum amid Trikafta’s international headwinds. Vertex stock shows a bullish technical bias despite recent pullback and mixed short-term ...

The message is that Journavx is off to a strong start in its acute pain debut, with good momentum across hospital and retail settings and broad shelf availability, reportedly on close to 90% of U ...

The FDA’s January 2025 approval of Journavx (suzetrigine), a non-opioid oral pain treatment, further contributed to the company’s market capitalisation growth. Gilead Sciences witnessed a ...